Central somatostatin (octreotide) attenuated the GH secretagogue-induced activation of arcuate nucleus neurons, demonstrating that somatostatin can oppose GHRP action at the hypothalamic level.
Central GHRP blockade by somatostatinOctreotide pre-treatment significantly reduced GHRP-induced arcuate nucleus activation
What the researchers found
Octreotide (somatostatin analog) attenuated GH secretagogue-induced Fos expression in the arcuate nucleus, showing somatostatin opposes GHRP action centrally.
Why it matters
Understanding that somatostatin can block GHRP effects in the brain explains why high somatostatin states (like elevated blood sugar) can reduce GHRP efficacy.
How the study worked
Conscious male rats received IV octreotide (100 µg) or saline 10 minutes before IV GH secretagogue injection. Brains were processed for Fos protein immunohistochemistry.
What this study cannot tell us
Animal study using pharmacological somatostatin analog (octreotide) at a specific dose. Natural somatostatin dynamics may differ. Fos expression is an indirect marker.
How to read the evidence
Moderate animal evidence with clear pharmacological demonstration in conscious rats.
When this study was published
Published in 1997, informing current understanding of optimal GHRP timing relative to meals and blood sugar.
The bigger picture
This finding explains why GHRPs work best when somatostatin tone is low (fasting, nighttime) and less well after meals or in high-glucose states.
Questions still open
- Is the somatostatin-GHRP interaction at the hypothalamus clinically significant?
- Can timing GHRP administration around somatostatin fluctuations optimize GH response?
Common questions
Why does somatostatin matter for GHRP users?
What is octreotide?
Read the original research
Attenuation of the growth hormone secretagogue induction of Fos protein in the rat arcuate nucleus by central somatostatin action.
Neuroendocrinology, 66(3), 188-94
Citation
Dickson, S L; Viltart, O; Bailey, A R; Leng, G. (1997). Attenuation of the growth hormone secretagogue induction of Fos protein in the rat arcuate nucleus by central somatostatin action.. Neuroendocrinology, 66(3), 188-94.